Summary: A method for the determination of glucose is described. H 2 0 2 , produced by the action of glucose oxidase, is measured from the change in absorbance due to oxidation of NAD(P)H in the presence of catalase, aldehyde dehydrogenase and a high concentration of ethanol. The quality data of the method are equivalent to those of the hexokinase-glucose-6-phosphate dehydrogenase method used as reference.
Introduction
Glucose determination is one of the most frequently used methods in clinical chemistry, and is based mainly on three enzymatic-photometric assays: the NADP dependent hexokinase-glucose-6-phosphäte dehydrogenase method (1), the NAD-dependent glucose dehydrogenase method (2) and the H 2 0 2 -producing glucose oxidase-peroxidase method coupled with leuco dyes (3).
Our assay is based on the glucose oxidase reaction, with measurement of the produced H 2 O 2 , using catalase and NAD(P)-dependent aldehyde dehydrogenase in the presence of high ethanol concentrations. This principle (4) , which has already been evaluated for uric acid (5) and cholesterol (6) avoids the known difficulties arising from the use of peroxidäse coupled with leuco dyes.
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Results
The accuracy of the method was established by determining the glucose concentration in aqueous solutions of known glucose concentrations, in control sera containing known concentrations and by determination of the glucose concentration in patients' sera with our method and the hexokinase-glucose-6-phosphate dehydrogenase method (1). The results of both methods were compared with the paired-t-test, which did not show significant differences. The regression analysis for patients' sera is shown in figure 1 . The precision from day to day for control sera was CV < 3.08% (n = 55), which almost meets the figure of the American College of Pathologist* (CV < 2.2%) (7), and which is well below the requirements of the guidelines of the Medical Society of the Federal Republic of Germany (CV < 5%) (7).
For normal sera or those with slight haemolysis, hyperlipidaemia or hyperbilirubinaemia, the absorbance value of the sample is negligible. For strongly haemolytic samples, turbid hyperlipidaemic samples or samples with well elevated bilirubin levels (> 115 ìðéïÀ/ß), the absorbance value of the sample volume has to be determined in a reaction mixture without glucose oxidase, and then subtracted.
Discussion
The described method is suitable for the determination of glucose in human sera. The linear range of the method was verified for concentrations from 2-38 mmol/1, thus permitting determination of almost any normal or pathologic glucose concentration.
Relevant inhibitor substances for glucose oxidase or aldehyde dehydrogenase are not known in human sera.
For the evaluation of a uric acid determination method, which has the same indicator system, a number of substances often used clinically were tested for possible interference. No interference by these substances was noted (5).
Compared to other glucose oxidase methods coupled with leuco dyes, our method has several advantages: The reaction time is 10-15 min shorter. The glucose concentration can be calculated directly from the absorbance difference using the coefficient of absorbance for NAD(P)H. Stabilisation of the indicator is not necessary. The manual procedure for our method is rather simple and it can be easily automatized.
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decreased excretion of creatmine in young children (9, 10), rather than by an increased level of cyclic GMP. The upper limit of urinary excretion of cyclic GMP in children younger than two years, is 5 ìðéïÀ/g creatinine; whereas the normal range in children older than 2 years is 0.5-1.2 ìðéïÀ/g creatinine. The normal level of cyclic GMP in plasma has been determined as 1.2 nmol/1; this level is extremely constant. As shown in figure 2, elevated excretion rates of cyclic GMP were found in children with treated and untreated malignant tumours. The excretion rates of some untreated tumour patients were ten times the normal level as shown in figure 1 . The mean increase in cyclic GMP excretion was lower in patients who were already under radio-or chemotherapy when the first analysis was made ( fig. 2 ). Brain tumours, with 2 exceptions, yielded little or no elevation of the cyclic GMP excretion rate. Table 1 shows 186 determinations of the excretion rates of cyclic GMP in 70 children older than 2 years bearing malignant tumours or lymphoproliferative diseases. The highest percentage of elevated rates was found in patients with untreated malignant tumours (69 of 87), while in patients with malignant tumours undergoing treatment as well as with malignant tumours in remission the ratio was considerably lower (10 of 51 and 17 of 48, respectively). In a control group of 85 patients with other nonproliferative diseases, 20 also had elevated excretion rates. Follow-up studies up to 3 years revealed that urinary cyclic GMP excretion drops to near normal values in patients during remission of their disease, while recurrences are accompanied or preceded by a rise of cyclic GMP excretion. In cases of Wilms tumour ( fig. 3) nephrectomy was followed by a drastic drop of cyclic GMP excretion. Another patient ( fig. 4) Together with other clinical parameters the determination of urinary excretion of cyclic GMP seems to be useful for tumour diagnosis and the assessment of therapeutic response in children. So far, the excretion rate of cyclic GMP cannot be correlated with the size or clinical stage of localized tumours, since the number of cases of each type of tumour was too low. However, in 12 patients with acute lymphatic leukaemia we found that there is no correlation between cyclic GMP and haematological findings.
The determination of cyclic GMP in the urine is of no use for the diagnosis of gynaecological tumours. For other malignant tumours in adults, the measurement of cyclic GMP in urine has approximatively the same value as other in vitro tests available. None of the established in vitro tests gives positive results for all tumour cases. The confidence level of tumour diagnosis by in vitro tests increases with the number of independent tests. In this sense, the determination of cyclic GMP excretion in urine complements the list of in vitro tumour tests.
